Skip to main content

ORACEA® (doxycycline, USP) CAPSULES 40 MG*

The only oral treatment specifically designed to effectively treat inflammatory lesions of rosacea, without crossing the antimicrobial threshold1-3

*30 mg immediate release & 10 mg delayed release beads

Trust ORACEA® (doxycycline, USP) Capsules 40 mg* for powerful anti-inflammatory effects1,2

The safety and efficacy of ORACEA Capsules in the treatment of inflammatory lesions (papules and pustules) of rosacea was evaluated in two randomized, placebo-controlled, multi-centered, double-blind, 16-week Phase 3 trials involving 537 subjects (total of 269 subjects on ORACEA from the two trials) with rosacea (10 to 40 papules and pustules and two fewer nodules).1,5

Mean change in lesion count ORACEA Capsules vs Placebo : Study 1 -11.8 vs -5.9, Study 2 -9.5 vs -4.3

Most common adverse events (>2%) were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase.

  • Unique formulation* with anti-inflammatory effects equivalent to doxycycline 100 mg2,5-9
  • Superior GI tolerability vs doxycycline 100 mg2
    ORACEA Capsules did not include symptoms of nausea, diarrhea, vomiting or abdominal pain4,5
  • No evidence of bacterial resistance in a 9-month study4

The potent anti-inflammatory effect of doxycycline

The mechanism of action of ORACEA Capsules (30 mg immediate release and 10 mg delayed-release doxycycline) in the treatment of inflammatory lesions of rosacea is unknown. In a clinical study, the effective formulation of ORACEA Capsules resulted in early and significant inflammatory lesion reduction.1

Learn More

ORACEA® 40 mg* Capsules provide sustained anti-inflammatory effect with low plasma variability10,11

Sixteen healthy subjects in the ORACEA Capsules arm measured at 7 days; mean weight 75kg

The precisely formulated non-antibiotic dose makes a difference

The non-antibiotic dose, with immediate and delayed-release beads, is specifically engineered to remain below the antimicrobial threshold.

Learn More